{"id":"methotrexate-plus-sulfasalazine","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea and gastrointestinal upset"},{"rate":"5-15","effect":"Bone marrow suppression (leukopenia, thrombocytopenia)"},{"rate":"5-10","effect":"Hepatotoxicity"},{"rate":"5-10","effect":"Infection"},{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methotrexate is a folate antagonist that inhibits dihydrofolate reductase, reducing DNA synthesis and cell proliferation in rapidly dividing immune cells. Sulfasalazine is cleaved into sulfapyridine and 5-aminosalicylic acid, which reduce inflammatory mediators and modulate immune responses. The combination provides synergistic anti-inflammatory and immunosuppressive effects.","oneSentence":"Methotrexate and sulfasalazine together suppress immune-mediated inflammation by inhibiting dihydrofolate reductase and reducing bacterial antigen processing, respectively.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:27.660Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Active inflammatory arthritis"}]},"trialDetails":[{"nctId":"NCT07497282","phase":"PHASE2","title":"Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2026-03-26","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT05671497","phase":"PHASE2, PHASE3","title":"The Effect of Cilostazol on Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT03739853","phase":"PHASE4","title":"Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-14","conditions":"Psoriatic Arthritis","enrollment":192},{"nctId":"NCT04435288","phase":"PHASE3","title":"Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-08-24","conditions":"Peripheral Spondyloarthritis","enrollment":90},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT03254589","phase":"PHASE4","title":"Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Flinders University","startDate":"2017-10-01","conditions":"Rheumatoid Arthritis, Stiffness, Aortic, Endothelial Dysfunction","enrollment":124},{"nctId":"NCT03531073","phase":"","title":"Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-04-18","conditions":"Psoriatic Arthritis","enrollment":446},{"nctId":"NCT06753565","phase":"PHASE2","title":"L-carnitine Supplementation in Rheumatoid Arthritis Patients","status":"RECRUITING","sponsor":"German University in Cairo","startDate":"2024-12-31","conditions":"Rheumatoid Arthritis (RA)","enrollment":60},{"nctId":"NCT03660059","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2018-09-27","conditions":"Rheumatoid Arthritis (RA)","enrollment":385},{"nctId":"NCT06640309","phase":"PHASE2","title":"The Effect of Nicotinamide on the Clinical Outcome of Rheumatoid Arthritis Patients","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2023-12-02","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT06594822","phase":"PHASE3","title":"Effectiveness of Probiotics in Patients of Mild to Moderate Rheumatoid Arthritis","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2023-08-24","conditions":"Rheumatoid Arthritis","enrollment":88},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT05458531","phase":"","title":"Monitoring of Inflammatory Conditions","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2022-06-28","conditions":"Inflammatory Disease, Crohn Disease, Ulcerative Colitis","enrollment":664},{"nctId":"NCT05447520","phase":"PHASE2","title":"Montelukast Use in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Noha Mansour","startDate":"2021-12-15","conditions":"Rheumatoid Arthritis","enrollment":92},{"nctId":"NCT05871086","phase":"PHASE2, PHASE3","title":"Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients","status":"UNKNOWN","sponsor":"Nourhan Elsherif","startDate":"2023-05-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT02374021","phase":"PHASE4","title":"Treatments Against RA and Effect on FDG-PET/CT","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-07","conditions":"Arthritis, Rheumatoid","enrollment":159},{"nctId":"NCT01491815","phase":"PHASE4","title":"Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2012-12-14","conditions":"Rheumatoid Arthritis","enrollment":812},{"nctId":"NCT02466581","phase":"PHASE4","title":"Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2015-02-03","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT05424393","phase":"","title":"Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-03-04","conditions":"Rheumatoid Arthritis","enrollment":500},{"nctId":"NCT04434118","phase":"","title":"Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-03-20","conditions":"Rheumatoid Arthritis, COVID","enrollment":""},{"nctId":"NCT03449758","phase":"PHASE4","title":"Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-05","conditions":"Rheumatoid Arthritis","enrollment":84},{"nctId":"NCT05051137","phase":"","title":"Real-World Emulation of the SWEFOT Trial","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2006-01-12","conditions":"Rheumatoid Arthritis","enrollment":509},{"nctId":"NCT04268394","phase":"PHASE1","title":"A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677","status":"COMPLETED","sponsor":"Celgene","startDate":"2020-03-13","conditions":"Healthy Volunteer","enrollment":48},{"nctId":"NCT02930343","phase":"PHASE3","title":"Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy","status":"TERMINATED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2016-09","conditions":"Rheumatoid Arthritis","enrollment":136},{"nctId":"NCT04927000","phase":"PHASE4","title":"The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-05-31","conditions":"Rheumatoid Arthritis","enrollment":170},{"nctId":"NCT02873936","phase":"PHASE3","title":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Rheumatoid Arthritis","enrollment":449},{"nctId":"NCT03797872","phase":"PHASE4","title":"Psoriatic Oligoarthritis Intervention With Symptomatic thErapy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-04-17","conditions":"Psoriatic Arthritis","enrollment":1},{"nctId":"NCT02320630","phase":"NA","title":"Combination Therapy Prevents the Relapse of RA","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2015-10","conditions":"Recurrence (Disease Attribute)","enrollment":240},{"nctId":"NCT04077957","phase":"PHASE4","title":"Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-10-07","conditions":"Ankylosing Spondylitis, Spondyloarthritis","enrollment":100},{"nctId":"NCT02433184","phase":"PHASE4","title":"Very Early Versus Delayed Etanercept in Patients With RA","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":120},{"nctId":"NCT04066803","phase":"PHASE4","title":"Optimal MTX Dose With Folic Acid Randomized Case-control Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-08-01","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT03863405","phase":"PHASE2","title":"Metformin Use in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-01-09","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT03813771","phase":"PHASE4","title":"Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2019-03","conditions":"Rheumatoid Arthritis","enrollment":106},{"nctId":"NCT01941095","phase":"PHASE3","title":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-20","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT03610217","phase":"NA","title":"Pragmatic Clinical Trials in Scleroderma","status":"UNKNOWN","sponsor":"University of West London","startDate":"2018-10","conditions":"Scleroderma, Systemic, Sclerosis, Systemic","enrollment":400},{"nctId":"NCT02293681","phase":"","title":"An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-04-10","conditions":"Spondylitis, Ankylosing","enrollment":76},{"nctId":"NCT01709578","phase":"PHASE3","title":"To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":546},{"nctId":"NCT01768572","phase":"PHASE3","title":"To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":202},{"nctId":"NCT02057250","phase":"PHASE3","title":"To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":"RA","enrollment":217},{"nctId":"NCT00521924","phase":"PHASE3","title":"Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Rheumatoid Arthritis","enrollment":8},{"nctId":"NCT01313208","phase":"PHASE4","title":"Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":210},{"nctId":"NCT01689532","phase":"PHASE3","title":"A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2012-11","conditions":"Arthritis, Rheumatoid","enrollment":122},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT00848354","phase":"PHASE4","title":"Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Rheumatoid Arthritis","enrollment":429},{"nctId":"NCT01015547","phase":"PHASE3","title":"Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2003-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT00908089","phase":"PHASE4","title":"TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"University of Helsinki","startDate":"2003-03","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT02376478","phase":"","title":"On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2009-12","conditions":"Psoriasis, Inflammatory Bowel Diseases","enrollment":222},{"nctId":"NCT01659242","phase":"PHASE4","title":"Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study","status":"TERMINATED","sponsor":"Singapore General Hospital","startDate":"2012-07","conditions":"Rheumatoid Arthritis","enrollment":1},{"nctId":"NCT00720798","phase":"PHASE3","title":"An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-09","conditions":"Rheumatoid Arthritis","enrollment":2067},{"nctId":"NCT00405275","phase":"NA","title":"Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2007-07","conditions":"Rheumatoid Arthritis","enrollment":353},{"nctId":"NCT01040195","phase":"PHASE3","title":"Combination Disease-Modifying Antirheumatic Drugs (DMARDs) Versus Sulfasalazine in Inflammatory Back Pain","status":"COMPLETED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2009-06","conditions":"Seronegative Spondyloarthropathies","enrollment":33},{"nctId":"NCT00520572","phase":"PHASE2","title":"A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-08","conditions":"Rheumatoid Arthritis","enrollment":385},{"nctId":"NCT00531817","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Rheumatoid Arthritis","enrollment":619},{"nctId":"NCT00706797","phase":"PHASE4","title":"Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":141},{"nctId":"NCT01211834","phase":"PHASE3","title":"Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT00422227","phase":"PHASE4","title":"Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-06","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT00764725","phase":"PHASE4","title":"Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":487}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":75,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Methotrexate plus sulfasalazine","genericName":"Methotrexate plus sulfasalazine","companyName":"Singapore General Hospital","companyId":"singapore-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methotrexate and sulfasalazine work together as disease-modifying antirheumatic drugs (DMARDs) by suppressing immune cell proliferation and reducing inflammatory cytokine production. Used for Rheumatoid arthritis, Other inflammatory arthropathies.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}